Bromazolam Stats & Data
Brc1ccc2c(c1)C(=NCc1nnc(C)n12)c1ccccc1KCEIOBKDDQAYCM-UHFFFAOYSA-NReceptor Profile
Receptor Actions
History & Culture
Bromazolam was first synthesized in 1976 as part of benzodiazepine research, representing a structural modification of alprazolam where the chlorine atom is replaced with bromine. Despite its early synthesis, the compound was never developed as a pharmaceutical product or brought to market for medical use. The substance remained largely obscure until it emerged in the designer drug market decades later. In 2016, bromazolam was definitively identified by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) after appearing in Sweden, marking its entry into the novel psychoactive substances landscape. Since then, it has become one of the more prevalent novel benzodiazepines in circulation. In parts of North America, particularly Canada, bromazolam has become intertwined with the illicit opioid supply. Street-level products combining bromazolam with opioids such as heroin or fentanyl analogues have emerged, sometimes referred to colloquially as "benzo-dope." This adulteration pattern has raised significant public health concerns due to the compounded risks of combining central nervous system depressants.
Effect Profile
Curated + 3 ReportsStrong anxiolysis and euphoria with strong cognitive impairment, mild sedation
Tolerance & Pharmacokinetics
drugs.wikiNo tolerance chart. Our decay curves for these drugs were estimates, and a curve can make tolerance look longer-lasting than it is, which is the dangerous direction.
How fast tolerance to these drugs fades after a break has not been measured well enough to draw, so don't count on a dose you used to take still being safe: after time off, start with a much smaller amount and don't use alone. Mixing sedatives with each other, with alcohol or with opioids sharply raises the risk of a fatal overdose. If you've been using regularly, don't stop suddenly: withdrawal from benzodiazepines, alcohol or GHB/GBL can cause seizures or delirium, so get medical help to cut down gradually.
Sources: FRANK: benzodiazepines · Alcohol and Drug Foundation: GHB · FDA 2020: benzodiazepine boxed warning · FDA 2019: gabapentinoids and breathing · NHS: alcohol use disorder
Cross-Tolerances
Experience Report Analysis
ErowidDemographics
Gender Distribution
Too few reports for a chart: gender is known from 4 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?
- Male 3 of 4
- Not Specified 1 of 4
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 3 experience reports (3 single-substance Erowid)
Effect Sentiment Distribution
Confidence Distribution
Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.
Too few reports for bars: these effects come from 3 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?
Positive Effects 1
Adverse Effects 0
Also reported in combinations. In the 1 Bromazolam report where another drug was taken too, 0 mention hospital, emergency services or an overdose, 1 a seizure and 0 psychosis (too few reports for percentages). In the 3 single-substance reports: 0, 0 and 0. These are not in the figures above: they cannot be put down to Bromazolam alone, and a mention is not always something that happened to the writer.
Form / Preparation
Most common forms and preparations, as a share of the 2 reports that give one
Too few reports for bars: these forms come from 2 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?
- Liquid 2 of 2
Legal Status
| Country | Status | Notes |
|---|---|---|
| United Kingdom | Class C | Classified as a Class C controlled substance under UK drug control legislation. Class C represents the lowest tier of controlled substances, with possession, supply, and production without authorization constituting criminal offenses. |
| United States | Unscheduled (federal); Schedule I pending January 2026 | Currently unscheduled at the federal level. Pursuant to a Drug Enforcement Administration notice, bromazolam will be placed into Schedule I on January 14, 2026 for two years with a possible one-year extension. Several states, including Virginia, have independently classified bromazolam as Schedule I at the state level, though notably excluding the related analog phenazolam. Despite its current federal unscheduled status, arrests have occurred for mismarketing bromazolam as alprazolam in counterfeit Xanax-shaped tablets, resulting in counterfeit drug charges. The U.S. Department of Justice reported in June 2022 that bromazolam seizures were surging nationwide, frequently detected alongside fentanyl in the illicit drug supply. |
References
Data Sources
Cited References
- Balasanova & Johnson (2022) - Phenibut and Bromazolam Use Disorders Case Report
- Bluelight: Forum - Bromazolam Weekend Use Discussion
- CREW Scotland - What is Bromazolam Harm Reduction Guide
- Ehlers et al. (2024) - CDC MMWR: Seizures and Myocardial Injury from Counterfeit Alprazolam
- Isomer Design - PIHKAL Entry for Bromazolam
- KnowYourStuff NZ - Bromazolam and Novel Benzos Guide
- Manchester et al. (2018) - The Emergence of NPS Benzodiazepines Review (DOI)
- Pichini et al. (2020) - Designer Benzodiazepines Literature and Trip Reports Analysis
- PsychonautWiki: Bromazolam
- Public Health Scotland - RADAR Bromazolam Alert (2023)
- Substance UVic - Bromazolam in Down Supply (2022)
- TripSit: Combining Depressants Harm Reduction
- TripSit: Drug Combinations Wiki
- Tripsitter: Bromazolam Fact Sheet
- Webb et al. (2023) - Post Mortem Blood Bromazolam Concentrations Study (DOI)
- WHO Expert Committee on Drug Dependence - Bromazolam Critical Review (2023)
- TripSit Factsheet: Bromazolam